Plus Therapeutics, Inc. (PSTV)

Over the past six months, Plus Therapeutics' stock price has declined by 51.30% and experienced volatility. In March 2025, the company completed an underwritten equity financing, raising approximately $15.0 million, followed by a restructuring of that equity deal in June 2025. Analyst price targets have seen adjustments, with some decreases in November 2025, although the consensus rating remains "Moderate Buy" with a significant upside potential.

There is no direct information indicating significant demand seasonality for Plus Therapeutics, Inc.'s products or services. The demand for its product candidates, once approved, would primarily be driven by medical need rather than seasonal fluctuations.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering treatments for cancer and rare diseases, operating in the Biotechnology and Drug Discovery industry. The company develops targeted radiotherapeutics for cancers of the central nervous system (CNS), with major product candidates including REYOBIQ™ for CNS cancers and Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) for solid organ cancers. Plus Therapeutics also develops proprietary drug delivery platforms.

Plus Therapeutics, Inc. is headquartered in Houston, Texas, and maintains additional laboratories and state-of-the-art clean rooms to support development, manufacturing, and preclinical activities. While currently focused on its U.S. operations, the company is exploring opportunities for geographic expansion beyond the United States.

Plus Therapeutics has maintained a generally positive brand reputation among analysts, with a consensus rating of "Moderate Buy". Positive clinical trial results for REYOBIQ™ in Leptomeningeal Metastases have been presented. However, the substantial decline in stock price and significant shareholder dilution could pose challenges to investor confidence and overall brand perception.

Plus Therapeutics, Inc. has a mixed ownership structure, with relatively low institutional ownership ranging from approximately 0.80% to 3.28%, indicating that the company is largely retail-driven. Major institutional owners include Vanguard Group Inc., Altium Capital Management LP, and Geode Capital Management, Llc. Insider buying has been observed in August and November 2025.